Owing to its ability to raise plasma levels of factor VIII and von Willebrand factor levels, the synthetic vasopressin analogue desmopressin has become the mainstay of treatment for type 1 von Willebrand disease and mild hemophilia A. A long clinical experience with this drug for prevention or treatment of bleedings in these patients has been accumulated over the past 30 years, supporting its hemostatic effectiveness and safety. In this paper, we summarize the current knowledge on the mechanisms of action as well as its biological effects in patients with mild hemophilia A. The results of the most important clinical trials in this setting are also reviewed. Blood Coagul Fibrinolysis 21: 615-619 (c) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
The use of desmopressin in mild hemophilia A.
Zaffanello M.;Lippi G.
2010-01-01
Abstract
Owing to its ability to raise plasma levels of factor VIII and von Willebrand factor levels, the synthetic vasopressin analogue desmopressin has become the mainstay of treatment for type 1 von Willebrand disease and mild hemophilia A. A long clinical experience with this drug for prevention or treatment of bleedings in these patients has been accumulated over the past 30 years, supporting its hemostatic effectiveness and safety. In this paper, we summarize the current knowledge on the mechanisms of action as well as its biological effects in patients with mild hemophilia A. The results of the most important clinical trials in this setting are also reviewed. Blood Coagul Fibrinolysis 21: 615-619 (c) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
